Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alvircept sudotox
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Alvircept sudotox is a recombinant fusion protein that combines the first 178 amino acids of the extracellular domain of human CD4 with a truncated form of *Pseudomonas aeruginosa* exotoxin A (PE40). It was developed as an investigational antiviral agent targeting HIV infections. The drug acts by binding to the HIV envelope glycoprotein gp120 via its CD4 domain, thereby delivering the cytotoxic exotoxin specifically to HIV-infected cells expressing gp120, leading to cell death. Alvircept sudotox was studied in clinical trials for HIV infection but development has been discontinued[1][3][5][7].
- Other names
- alvircept sudotox
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on alvircept sudotox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alvircept sudotox.